What Lidocaina Jalea Treats: Main Uses and Benefits

The primary therapeutic use of this medication is to provide supportive relief for symptoms related to physical discomfort before or during necessary medical procedures. It is generally used for managing symptoms that interfere with daily comfort, assisting with managing acute symptoms that create noticeable physiological strain, such as localized pain or sharp sensation that arises during instrumentation. Clinical applications include assisting with maintaining functional stability during endourethral procedures and endotracheal intubation, which supports the patient during difficult episodes.

Lidocaine Jalea is also applied in addressing symptoms related to inflammatory or irritative states of mucous membranes, particularly those presenting with localized discomfort, such as in painful urethritis. It is used for managing symptom clusters that may become intense or disruptive, including burning and stinging sensations, and contributes to improved day-to-day comfort during symptomatic periods. The gel is used for easing symptoms stemming from localized surface issues, such as those caused by minor thermal injuries, abrasions, or small cuts. This supportive relief helps maintain a sense of stability when symptoms are more noticeable.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities, especially during symptomatic periods.”

Quick Fact: Relief for Localized Discomfort
Primary Symptom Focus	Symptoms related to Acute Procedural Discomfort, Burning, Stinging, and Tenderness
Common Clinical Scenarios	Endoscopic and Endourethral Procedures, Symptomatic Urethritis
Patient Benefit	Contributes to improved comfort and eases overall symptom burden

The official eligibility profile for Lidocaina Jalea (Lidocaine Hydrochloride 2% Jelly) is defined by regulatory documents, specifying populations for whom use is prohibited, restricted, or requires conditional caution.

Populations for Whom Use is Prohibited (Contraindications)

Classification	Population Group
Absolute	Known hypersensitivity to amide-type local anesthetics or any formulation components.
Absolute	Patients experiencing severe shock or severe heart block.
Absolute	Application to infected and/or severely traumatized mucosa (risk of rapid systemic absorption).

Restricted and Age-Related Eligibility

Use is subject to formal limitations or conditions based on a patient's status or age:

• Pediatric Use: The safety and effectiveness of the 2% jelly are not established for the general pediatric population. Infants under six months of age are more susceptible to certain blood disorders and require monitoring if use is necessary.
• Conditional Use: Use is restricted to reduced doses for older adults and patients who are acutely ill or debilitated.
• Condition-Specific Caution: Caution is required for patients with severe hepatic disease, as they are at a greater risk of developing toxic plasma concentrations due to impaired metabolism.
• Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed and the potential benefit outweighs the risk (FDA Pregnancy Category B). Caution is recommended for nursing women, as lidocaine is known to be excreted into human milk.

Official Regulatory Interaction Profile

Classification	Documented Interaction Summary
Pharmacokinetic Profile Alteration	Co-administration with certain medicines reduces lidocaine clearance, potentially increasing systemic exposure.
Pharmacodynamic Reinforcement	Additive toxic effects on the central nervous and cardiovascular systems when co-administered with other local anesthetics.
Risk of Methemoglobinemia	Co-exposure with oxidizing agents increases the risk of this condition.

Specific Interaction Statements

Official regulatory documents define the interaction profile by identifying specific drug classes that affect lidocaine's clearance and systemic effects.

• Exposure-Modifying Medicines: Medicines that reduce hepatic blood flow or inhibit liver enzymes, such as Cimetidine and Beta-blockers, can reduce lidocaine clearance and lead to higher plasma concentrations.
• Additive Toxic Effects: Co-use with other local anesthetics or Class III Anti-Arrhythmic Drugs may result in additive toxic effects, particularly on cardiac and neurological function.
• Risk Agents: The risk of developing methemoglobinemia is increased with concurrent use of Oxidizing Agents, including specific Nitrates/Nitrites and certain Antibiotics.
• Contraindication and Avoidance: Concurrent administration with Ergot-Type Oxytocic Drugs should be avoided due to the potential for severe, persistent hypertension.
• Timing-Based Restriction: For mucosal or oral application, food and chewing gum must not be taken for 60 minutes after use, as documented in the label to mitigate the risk of aspiration or biting trauma.
• Population Note: The potential for increased systemic exposure is heightened in patients with hepatic impairment, as this condition can prolong the elimination half-life.

Connection to the Overall Interaction Profile

Regulatory information structures the interaction profile around required monitoring for pharmacokinetic reduction in clearance and necessary caution regarding pharmacodynamic additive toxicity. The profile explicitly documents specific product avoidance rules and mandatory timing constraints for oral application, based on the product's function.

Lidocaine, the active pharmaceutical ingredient, functions primarily as a voltage-gated sodium channel blocker. This mechanism targets the neuronal membrane, specifically interacting with the Na v (sodium voltage) channel complex responsible for transmitting electrical signals along nerve axons.

Upon application, lidocaine diffuses into the nerve cell and binds to a specific site within the pore of the Na v channel, stabilizing the channel in its inactivated state. This molecular interaction physically inhibits the rapid influx of sodium ions ( Na^+) into the nerve axon.

The prevention of this ionic movement is crucial as sodium influx is the initiating event for the depolarization phase required to generate an action potential. By preventing depolarization, the threshold for nerve excitation is significantly elevated, and the rate of signal transmission is slowed or terminated. The resulting physiological consequence is a local, reversible blockade of afferent nerve impulse conduction confined to the site of application.

How to Use Lidocaina Jalea

This section describes clinical parameters for the administration of Lidocaine Jalea, including route, dosage, frequency, and administration technique.

---

Administration Route and Method

Lidocaine Jalea is indicated for Topical/Mucosal Instillation into the male and female urethra for lubrication and surface anesthesia, and for Topical Application to the external surface of endotracheal tubes. It is administered as a single, acute application immediately prior to or during the necessary medical procedure.

---

Dosing and Time Constraints

The dosage administered depends on the site and type of procedure, and maximum limits must be observed.

Application Site	Standard Dosing Volume (2% Jalea)
Male Urethra (Major Procedures)	Initial 15 mL (300 mg); up to an additional 15 mL may be used
Female Urethra (Procedures)	3 mL to 5 mL (60 mg to 100 mg)
Male Urethra (Catheterization)	5 mL to 10 mL (100 mg to 200 mg)

No more than 600 mg of lidocaine hydrochloride should be administered in any 12-hour period, establishing a clear limitation on frequency.

---

Key Procedural Requirements

Proper use involves specific steps to ensure the drug performs as intended. For male urethral instillation, the Jalea should be instilled slowly, followed by the application of a penile clamp for 5 to 10 minutes to allow for the development of adequate anesthesia before instrumentation. For endotracheal use, a moderate amount is applied to the external surface of the tube, with care taken to avoid introduction into the tube's inner lumen.

Population Considerations

Administration to certain populations requires dosage adjustments. Dosages are reduced for children, the elderly, and debilitated patients; the total dose for a child should not exceed 4.5 mg/kg of body weight. Furthermore, when calculating the dose, the total amount of lidocaine from all concurrently used formulations must be considered.

Recent Clinical Evidence

Clinical studies involving lidocaine jelly (jalea) primarily evaluate its use as a topical anesthetic lubricant to reduce pain and discomfort during invasive medical procedures. Research focuses on its effectiveness when applied to mucous membranes, particularly in the urogenital and anorectal areas.

---

Efficacy in Urological Procedures

A significant body of evidence examines the use of 2% lidocaine gel during procedures like urethral catheterization and flexible cystoscopy. Findings from systematic reviews and randomized controlled trials (RCTs) have been inconsistent, with some studies reporting significantly lower pain levels compared to placebo or plain lubricant, while others found no meaningful difference. The heterogeneity in results may be attributed to variations in anesthetic dose, application method, the time allowed for absorption, and the type of procedure performed.

For male urethral catheterization, some evidence suggests that lidocaine gel may reduce procedural pain when compared to non-anesthetic lubricating gels. However, similar benefits were not uniformly observed in young children undergoing the same procedure, where some trials noted greater pain during the instillation of the gel itself.

---

Use in Specialized Procedures

• Prostate Biopsy: Studies evaluating the transrectal application of lidocaine gel prior to transrectal ultrasound-guided prostate biopsy have reported mixed results. Some trials observed a significant reduction in patient-reported mean pain scores compared to plain lubricant, while others found no notable benefit, particularly when compared to other anesthetic techniques like periprostatic nerve block.
• Intravesical Injections: Research comparing the use of lidocaine gel alone versus lidocaine solution instillation with the gel for managing pain during intravesical botulinum toxin (BoNT) injections found no significant difference in overall pain scores between the two methods.

---

Safety Profile Summary

Safety data collected across various studies indicate that the 2% topical lidocaine gel is generally well-tolerated when used as directed in clinical settings. The risk of systemic absorption leading to toxicity is minimal when applied to intact mucous membranes and used within recommended limits. However, the potential for systemic effects remains a consideration, particularly if applied over large or compromised areas, or if the maximum dose is exceeded. There is ongoing surveillance for rare adverse events, and specialized populations like pediatric patients require careful adherence to safe use parameters.

Key Studies & References

1. Efficacy of 2% intraurethral lidocaine gel for pain control during flexible cystoscopy in men: a randomized controlled trial
2. Topical anesthetics for preventing pain during male paediatric urethral catheterisation: A systematic review and meta-analysis

Official Storage and Disposal Requirements

Lidocaine Hydrochloride Jelly must be stored strictly according to the conditions defined by regulatory labeling to maintain its stability and effectiveness.

Storage Conditions

• Temperature: Store at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions between 15 C and 30 C are permitted.
• Container and Protection: The medicine must be kept in its original container and the container must remain tightly closed. It is essential to store the product in a location that avoids excessive heat.
• Child Safety: Store the medication out of the reach of children.

Disposal Instructions

For products supplied in single-use packaging (such as the 2% concentration), the unused portion must be discarded after initial use. Any expired or otherwise unused Lidocaine Jalea should be disposed of in accordance with local requirements or by consulting a pharmacist.